C Turesson1,2, O Börjesson3, K Larsson4, A J Mohammad5,6, A Knight7. 1. a Rheumatology, Department of Clinical Sciences , Malmö, Lund University , Malmö , Sweden. 2. b Department of Rheumatology , Skåne University Hospital , Malmö , Sweden. 3. c Department of Rheumatology , Karolinska University Hospital , Stockholm , Sweden. 4. d Department of Rheumatology , Sahlgrenska University Hospital , Gothenburg , Sweden. 5. e Rheumatology, Department of Clinical Sciences, Lund , Lund University , Lund , Sweden. 6. f Department of Rheumatology , Skåne University Hospital , Lund , Sweden. 7. g Rheumatology, Department of Medical Sciences , Uppsala University , Uppsala , Sweden.
Abstract
Objective: To develop evidence-based guidelines for the management of giant cell arteritis (GCA) as a complement to guidelines in other areas of rheumatology, issued by the Swedish Society of Rheumatology. Methods: A working group selected key areas for recommendations, reviewed the available evidence, and wrote draft guidelines. These were discussed and revised according to standard procedures within the Swedish Society of Rheumatology, including a one-day meeting open to all members. For key recommendations, the quality of evidence was assessed according to GRADE. The final guidelines were approved by the Society board in March 2018. Results: The guidelines include recommendations on diagnostic procedures, pharmacological treatment, follow-up, and adjuvant treatment. Ultrasonography is complementary to temporal artery biopsy (TAB) in the diagnostic work-up. Other imaging techniques (magnetic resonance imaging and positron emission tomography/computed tomography) are important in evaluating large-vessel involvement. Glucocorticoids (oral, or intravenous in cases with ischaemic complications) remain the first line treatment for GCA. Addition of tocilizumab is recommended for patients with relapsing disease who meet five criteria, representing active disease that has been objectively verified by TAB or imaging. Tocilizumab may also be considered in patients with newly diagnosed GCA who are at major risk of severe glucocorticoid side effects. Based on current evidence, tocilizumab treatment for > 1 year cannot be recommended. Conclusion: These guidelines are based on current evidence and consensus within Swedish rheumatology. Following major developments in diagnostics and treatment of GCA, such guidelines are important for clinical practice, and should be updated on a regular basis.
Objective: To develop evidence-based guidelines for the management of giant cell arteritis (GCA) as a complement to guidelines in other areas of rheumatology, issued by the Swedish Society of Rheumatology. Methods: A working group selected key areas for recommendations, reviewed the available evidence, and wrote draft guidelines. These were discussed and revised according to standard procedures within the Swedish Society of Rheumatology, including a one-day meeting open to all members. For key recommendations, the quality of evidence was assessed according to GRADE. The final guidelines were approved by the Society board in March 2018. Results: The guidelines include recommendations on diagnostic procedures, pharmacological treatment, follow-up, and adjuvant treatment. Ultrasonography is complementary to temporal artery biopsy (TAB) in the diagnostic work-up. Other imaging techniques (magnetic resonance imaging and positron emission tomography/computed tomography) are important in evaluating large-vessel involvement. Glucocorticoids (oral, or intravenous in cases with ischaemic complications) remain the first line treatment for GCA. Addition of tocilizumab is recommended for patients with relapsing disease who meet five criteria, representing active disease that has been objectively verified by TAB or imaging. Tocilizumab may also be considered in patients with newly diagnosed GCA who are at major risk of severe glucocorticoid side effects. Based on current evidence, tocilizumab treatment for > 1 year cannot be recommended. Conclusion: These guidelines are based on current evidence and consensus within Swedish rheumatology. Following major developments in diagnostics and treatment of GCA, such guidelines are important for clinical practice, and should be updated on a regular basis.
Authors: Thomas Daikeler; Peter M Villiger; Christophe Schmitt; Laura Brockwell; Mylène Giraudon; Mauro Zucchetto; Lisa Christ; Bettina Bannert Journal: Arthritis Res Ther Date: 2022-06-04 Impact factor: 5.606
Authors: Dan Pugh; Maira Karabayas; Neil Basu; Maria C Cid; Ruchika Goel; Carl S Goodyear; Peter C Grayson; Stephen P McAdoo; Justin C Mason; Catherine Owen; Cornelia M Weyand; Taryn Youngstein; Neeraj Dhaun Journal: Nat Rev Dis Primers Date: 2022-01-06 Impact factor: 65.038
Authors: Karin Wadström; Lennart Jacobsson; Aladdin J Mohammad; Kenneth J Warrington; Eric L Matteson; Carl Turesson Journal: Rheumatology (Oxford) Date: 2020-11-01 Impact factor: 7.580
Authors: Pavlos Stamatis; Aleksandra Turkiewicz; Martin Englund; Carl Turesson; Aladdin J Mohammad Journal: Rheumatology (Oxford) Date: 2021-12-24 Impact factor: 7.580